eliquis apixaban eliquis apixaban eliquis apixaban logo

This information is intended for healthcare professionals based in the UK.

If you are not a healthcare professional in the UK, please click here.

For Prescribing and Adverse Event reporting information, click here.

desk-img mob-img
Home > HCP > Dosing and Switching > Dosing in NVAF

RECOMMENDED ELIQUIS (APIXABAN) DOSING FOR STROKE PREVENTION IN NVAF WITH ONE OR MORE RISK FACTORS1

mob-img

In the ARISTOTLE clinical trial, the majority of patients were on 5 mg BD (95.3%, n = 8,692/9,120).2†

mob-img
  • Eliquis is not recommended in patients with CrCl <15ml/min or in patients undergoing dialysis
  • The use of Eliquis is not recommended in patients receiving concomitant systemic treatment with strong inhibitors of both CYP3A4 and P-gp. For the prevention of stroke and systemic embolism in patients with NVAF and for the prevention of recurrent DVT/PE, Eliquis should be used with caution in patients receiving concomitant systemic treatment with strong inducers of both CYP3A4 and P-gp. For the treatment of DVT /PE, in patients receiving concomitant systemic treatment with strong inducers of both CYP3A4 and P-gp, Eliquis should not be used since efficacy may be compromised. See SmPC for complete information on drug-drug interactions.

      • ELIQUIS is a convenient, oral treatment for patients

      Freedom from INR monitoring1

      No dietary restrictions and the choice to be taken with or without food1

      large x icon

      If a dose is missed, take ELIQUIS immediately and then continue with twice-daily intake as before1

      icon2

      Liver function testing should be performed prior to initiating ELIQUIS1
Purple information icon ELIQUIS (apixaban) SmPC

Please click here to access the ELIQUIS SmPC.

Purple information icon ELIQUIS (apixaban) Patient Information Leaflet

Please click here to access the ELIQUIS Patient Information Leaflet.

BD = Twice Daily CrCl = Creatinine Clearance CYP3A4 = Cytochrome P450 3A4 INR = International Normalised Ratio ISTH = International Society on Thrombosis and Haemostasis LMWH = Low Molecular Weight Heparin NVAF = Non-Valvular Atrial Fibrillation P-gp = P-glycoprotein

† The ARISTOTLE clinical trial was a randomised, double-blind, double-dummy non-inferiority trial in 18,201 patients. Stroke / systemic embolism was the primary efficacy endpoint and major bleeding was the primary safety endpoint. The primary safety outcome was major bleeding, according to the criteria of the International Society on Thrombosis and Haemostasis (ISTH). Pre-specified hierarchical sequential testing was performed first on stroke / systemic embolism (primary efficacy endpoint) for non-inferiority, then for superiority, then on major bleeding and, finally, on death from any cause (secondary endpoint).2

References:

  1. ELIQUIS® (apixaban) Summary of Product Characteristics.
  2. Granger CB et al. N Engl J Med 2011; 365: 981–992.

You may contact our EU Data Protection Officer at EUDPO@BMS.com to exercise any data privacy rights that you may have, as well as to raise any concerns or questions in relation to the handling of your personal data by Bristol-Myers Squibb Company.

bristol myers squibb logo

© 2020 Bristol-Myers Squibb Pharmaceuticals Limited

All corporate names and logos of BMS and/or of its products are trademarks of Bristol-Myers Squibb Company and are protected by national and international intellectual and industrial property laws. All rights reserved over the content of this website.

Your use of this website is subject to the Legal Notice, the Privacy and Cookie Policy, the Pharmacovigilance Notice and the applicable laws and regulations.

432UK2000391-02
Date of preparation May 2020